Atea Pharmaceuticals is trading 5% higher at $4.30 on November 3, 2026, alongside biotech-sector strength; available reports did not identify a new company-specific catalyst. - Biotech ETF XBI is up 2.13% during the session. - Atea will report third-quarter results and provide a business update on November 9; the scheduled call does not establish a direct reason for today’s move.